Bipolar Disorders in Saudi Arabia: What Do We Know So Far?

被引：0
|
作者：
Almadani, Ahmad H. [1 ,2 ]
Alhadi, Ahmad N. [1 ,2 ,3 ]
Aldawood, Buthainah D. [4 ]
Aleissa, Mariam M. [5 ,6 ]
Alosaimi, Fahad D. [1 ,2 ]
机构：
[1] King Saud Univ, Coll Med, Dept Psychiat, Riyadh, Saudi Arabia
[2] King Saud Univ, King Saud Univ Med City, Dept Psychiat, Riyadh, Saudi Arabia
[3] King Saud Univ, Coll Med, SABIC Psychol Hlth Res & Applicat Chair, Riyadh, Saudi Arabia
[4] Princess Nourah bint Abdulrahman Univ, Coll Hlth & Rehabil Sci, Dept Clin Psychol, Riyadh, Saudi Arabia
[5] Publ Hlth Lab, Dept Mol Genet, Publ Hlth Author, Riyadh, Saudi Arabia
[6] Alfaisal Univ, Med Sch, Riyadh, Saudi Arabia
来源：
SAUDI JOURNAL OF MEDICINE & MEDICAL SCIENCES | 2025年 / 13卷 / 01期
关键词：
Bipolar disorders; clinical manifestations; epidemiology; etiology; psychotropic medications; Saudi Arabia; OUTPATIENT PSYCHIATRIC SETTINGS; PREVALENCE; PATTERNS; INPATIENT; DIAGNOSES; STIGMA;
D O I：
10.4103/sjmms.sjmms_306_24
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Bipolar disorders (BP) are prevalent neuropsychiatric illnesses affecting 1%-5% of the global population and about 3% of the Saudi population. They are associated with significant comorbidities and negative consequences. Despite being common mental health conditions in Saudi Arabia, stigma persists, with weak character, supernatural beliefs, and weak faith considered as causes. In addition, Saudi patients with BP have been reported to seek help from non-psychiatric healthcare professionals and faith healers. More data are required on BP from Saudi Arabia, including the genetic aspects and their treatment approaches. This narrative review paper explores the epidemiology and clinical manifestations, etiology and biological mechanisms, public knowledge and awareness of the illnesses, and treatment of BP in Saudi Arabia.
引用
收藏
页码：1 / 6
页数：6
相关论文
共 50 条
  • [31] Naming: What Do We Know So Far? A Systematic Review
    Sivaraman, Maithri
    Barnes-Holmes, Dermot
    PERSPECTIVES ON BEHAVIOR SCIENCE, 2023, 46 (3-4) : 585 - 615
  • [32] Atherosclerosis in HIV Patients: What Do We Know so Far?
    Poznyak, Anastasia V.
    Bezsonov, Evgeny E.
    Borisov, Evgeny E.
    Grechko, Andrey V.
    Kartuesov, Andrey G.
    Orekhov, Alexander N.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (05)
  • [33] Sport and Autism: What Do We Know so Far? A Review
    Grospretre, Sidney
    Ruffino, Celia
    Derguy, Cyrielle
    Gueugneau, Nicolas
    SPORTS MEDICINE-OPEN, 2024, 10 (01)
  • [34] The cognitive effects of esketamine: what do we know so far?
    Barbosa, M.
    Guedes, R.
    EUROPEAN PSYCHIATRY, 2022, 65 : S728 - S728
  • [35] New Indications for TIPSs: What Do We Know So Far?
    Lapenna, Lucia
    Di Cola, Simone
    Gazda, Jakub
    De Felice, Ilaria
    Gioia, Stefania
    Merli, Manuela
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 13 (05) : 794 - 803
  • [36] Microplastics and freshwater microalgae: what do we know so far?
    Rani-Borges, Barbara
    Moschini-Carlos, Viviane
    Pompeo, Marcelo
    AQUATIC ECOLOGY, 2021, 55 (02) : 363 - 377
  • [37] Microplastics and freshwater microalgae: what do we know so far?
    Bárbara Rani-Borges
    Viviane Moschini-Carlos
    Marcelo Pompêo
    Aquatic Ecology, 2021, 55 : 363 - 377
  • [38] Epigenetics, hypersensibility and asthma: what do we know so far?
    Lima, Douglas da Silva
    Morais, Rahuany Velleda de
    Rechenmacher, Ciliana
    Michalowski, Mariana Bohns
    Goldani, Marcelo Zubaran
    CLINICS, 2023, 78
  • [39] Genetics and Epigenetics in Obesity: What Do We Know so Far?
    Keller, Maria
    Svensson, Stina Ingrid Alice
    Rohde-Zimmermann, Kerstin
    Kovacs, Peter
    Boettcher, Yvonne
    CURRENT OBESITY REPORTS, 2023, 12 (04): : 482 - 501
  • [40] Eosinophilic Esophagitis-What Do We Know So Far?
    Wasik, Jakub
    Malecka-Wojciesko, Ewa
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (06)
12345